Walgreens Boots Alliance Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Walgreens Boots Alliance wird ein jährliches Gewinn- und Umsatzwachstum von 67.6% bzw. 3.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 71.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 18.9% betragen.

Wichtige Informationen

67.6%

Wachstumsrate der Gewinne

71.1%

EPS-Wachstumsrate

Consumer Retailing Gewinnwachstum	9.2%
Wachstumsrate der Einnahmen	3.7%
Zukünftige Eigenkapitalrendite	18.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BMV:WBA * - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
8/31/2026	157,100	2,163	2,643	4,370	10
8/31/2025	150,749	1,806	2,207	3,977	16
8/31/2024	145,296	-7,176	1,389	3,006	16
2/29/2024	144,597	-6,037	-1,766	101	N/A
11/30/2023	142,406	574	-529	1,484	N/A
8/31/2023	139,081	-3,080	141	2,258	N/A
5/31/2023	136,108	-3,315	-821	1,305	N/A
2/28/2023	133,291	-3,144	982	2,954	N/A
11/30/2022	132,184	-2,964	1,403	3,293	N/A
8/31/2022	132,703	4,337	2,165	3,899	N/A
5/31/2022	134,516	5,111	3,439	5,058	N/A
2/28/2022	135,948	5,926	3,626	5,183	N/A
11/30/2021	134,972	5,965	4,057	5,459	N/A
8/31/2021	132,509	1,994	4,176	5,555	N/A
5/31/2021	128,617	1,972	4,983	6,396	N/A
2/28/2021	124,952	-926	4,195	5,556	N/A
11/30/2020	123,509	-981	4,200	5,618	N/A
8/31/2020	121,982	179	4,110	5,484	N/A
5/31/2020	125,566	519	4,359	5,777	N/A
2/29/2020	129,792	3,339	5,269	6,883	N/A
11/30/2019	132,984	3,628	4,576	6,195	N/A
8/31/2019	120,074	3,816	3,892	5,594	N/A
5/31/2019	136,354	4,817	4,402	6,032	N/A
2/28/2019	136,097	5,133	4,756	6,250	N/A
11/30/2018	134,590	5,326	6,261	7,720	N/A
8/31/2018	131,537	5,024	6,896	8,263	N/A
5/31/2018	128,244	4,314	6,038	7,460	N/A
2/28/2018	124,028	4,134	5,699	7,077	N/A
11/30/2017	120,453	3,845	N/A	7,729	N/A
8/31/2017	118,214	4,078	N/A	7,255	N/A
5/31/2017	116,701	4,306	N/A	7,895	N/A
2/28/2017	116,081	4,247	N/A	8,144	N/A
11/30/2016	116,819	4,117	N/A	7,640	N/A
8/31/2016	117,351	4,173	N/A	7,847	N/A
5/31/2016	117,237	3,169	N/A	6,694	N/A
2/29/2016	116,534	3,368	N/A	6,412	N/A
11/30/2015	112,923	4,480	N/A	5,365	N/A
8/31/2015	103,444	4,220	N/A	5,664	N/A
5/31/2015	93,979	3,973	N/A	5,543	N/A
2/28/2015	84,585	3,385	N/A	4,993	N/A
11/30/2014	77,617	2,059	N/A	4,791	N/A
8/31/2014	76,392	1,932	N/A	3,893	N/A
5/31/2014	75,276	2,810	N/A	3,632	N/A
2/28/2014	74,188	2,720	N/A	3,739	N/A
11/30/2013	73,230	2,760	N/A	3,833	N/A
8/31/2013	72,217	2,548	N/A	4,301	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: WBA * wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (7.8%).

Ertrag vs. Markt: WBA * wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: WBA * wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: WBA *Die Einnahmen des Unternehmens (3.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt MX (7.1% pro Jahr).

Hohe Wachstumseinnahmen: WBA *Die Einnahmen des Unternehmens (3.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: WBA *Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (18.9 %).

Walgreens Boots Alliance Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

Recent updates

Walgreens Boots Alliance, Inc. to Report Q3, 2024 Results on Jun 27, 2024

Walgreens Announces Launch of Walgreens Brand Naloxone HCI Nasal Spray

Walgreens Reportedly Contacts Potential Buyers for £7 Billion Boots Drugstore Chain

Second quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on June 12, 2024

Independent Director recently bought Mex$893k worth of stock

Executive VP & Global CFO recently bought Mex$1.9m worth of stock

New major risk - Financial position

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Upcoming dividend of US$0.25 per share at 4.5% yield

Walgreens Boots Alliance, Inc. Announces Executive Changes

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

Independent Director recently sold Mex$6.0m worth of stock

CEO & Director recently bought Mex$4.1m worth of stock

First quarter 2024 earnings released: US$0.078 loss per share (vs US$4.31 loss in 1Q 2023)

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on March 12, 2024

The Shareholder Commons, Inc Files a Notice of Exempt Solicitation to Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2023

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$3.57 loss per share (vs US$5.02 profit in FY 2022)

Walgreens Boots Alliance, Inc. Appoints Tim Wentworth as Chief Executive Officer, Effective October 23, 2023

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from S&P 100

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Walgreens Boots Alliance, Inc. Announces CEO Changes

Upcoming dividend of US$0.48 per share at 6.6% yield

High number of new directors

Walgreens Boots Alliance, Inc. Announces Departure of James Kehoe as Executive Vice President

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on September 12, 2023

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire 120 pharmacies in Texas, Louisiana and Arkansas from Brookshire Grocery Company.

Insider recently bought Mex$2.5m worth of stock

Third quarter 2023 earnings released: EPS: US$0.14 (vs US$0.33 in 3Q 2022)

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Upcoming dividend of US$0.48 per share at 6.1% yield

CEO & Director recently bought Mex$6.1m worth of stock

Second quarter 2023 earnings released: EPS: US$0.81 (vs US$1.02 in 2Q 2022)

Upcoming dividend of US$0.48 per share at 5.2% yield

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on March 10, 2023

Walgreens Reportedly Weighs $2 Billion Sale of Pharmacy Automation Unit

First quarter 2023 earnings released: US$4.31 loss per share (vs US$4.14 profit in 1Q 2022)

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

Walgreens Boots Alliance, Inc. to Report Q1, 2023 Results on Jan 05, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Independent Director recently sold Mex$13m worth of stock

Walgreens Boots Alliance, Inc. Announces Resignation of William Foote, the Board Lead Independent Director

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2022

Full year 2022 earnings released: EPS: US$5.02 (vs US$2.31 in FY 2021)

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into a definitive agreement to acquire remaining 45% stake in CareCentrix, Inc. for approximately $390 million.

John Standley to Leave as Executive Vice President of Walgreens Boots Alliance, Inc. on November 1, 2022

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire additional 30% stake in Shields Specialty Pharmacy Holdings, LLC from Welsh, Carson, Anderson & Stowe, Jack Shields & others for approximately $1.4 billion.

Walgreens Boots Alliance, Inc. to Report Q4, 2022 Results on Oct 13, 2022

Walgreens Boots Alliance, Inc. Announces Executive Appointments

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. Names Alethia Jackson Senior Vice President, ESG and Chief DEI Officer

Walgreens Boots Alliance, Inc. Announces Resignation of David J. Brailer as Member of the Board of Directors

Upcoming dividend of US$0.48 per share

Jnd Legal Administration Announces A Class Action Lawsuit in the U.S. District Court for the District of Arizona Against Defendants Theranos, Inc., Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Company

Walgreens Boots Alliance Increases Quarterly Dividend, Payable September 9, 2022

Third quarter 2022 earnings released: EPS: US$0.33 (vs US$1.28 in 3Q 2021)

Walgreens Boots Alliance Concludes Strategic Review and Decides to Retain Ownership of Its Successful Boots Business

Walgreens Launches Clinical Trial Business to Address Industrywide Access and Diversity Challenges and Redefine Patient Experience

Walgreens Boots Alliance, Inc. to Report Q3, 2022 Results on Jun 30, 2022

Walgreens Reportedly Gives A Few Extra Days for Bidders to Firm Up Offers

An unknown buyer acquired 2.9% stake in AmerisourceBergen Corporation (NYSE:ABC) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for $900 million.